Abstract Single-agent programmed cell death-1 inhibitors or its ligand (PD-1/PD-L1i) demonstrate low response rates in metastatic triple-negative breast cancer (mTNBC), though a subset of patients may achieve durable responses. Data evaluating combined PD-1/PD-L1i and cytotoxic T-lymphocyte–associated protein 4 inhibition (CTLA-4i) are limited. We performed a meta-analysis evaluating the efficacy of single- and dual-agent immune checkpoint inhibitors (ICI) in mTNBC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Qi
Contact Qi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack